Reversible carfilzomib-induced pulmonary arterial hypertension: don't take your eyes off the ball!

Shareable abstract

The proteasome inhibitor myeloma therapy, carfilzomib, is an increasingly reported cause of drug-induced PAH, which can be reversible. This case highlights the complexity of close monitoring for further pulmonary vascular complications during follow-up. https://bit.ly/3yvHxpk